new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors




Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22016011516404/28/16  new patent  Bicyclic heterocycles as fgfr4 inhibitors
32016007572103/17/16 Tricyclic heterocycles as bet protein inhibitors
42016006725303/10/16 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
52016004665002/18/16 Tricyclic heterocycles as bet protein inhibitors
62016002268501/28/16 Heterocyclylamines as pi3k inhibitors
72016002410901/28/16 Tricyclic fused thiophene derivatives as jak inhibitors
82016002411701/28/16 Heterocyclylamines as pi3k inhibitors
92016001569501/21/16 Tricyclic fused thiophene derivatives as jak inhibitors
102016000971101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
112016000971201/14/16 Imidazopyridines and imidazopyrazines as lsd1 inhibitors
122016000971401/14/16 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
132016000972001/14/16 Imidazopyrazines as lsd1 inhibitors
142016000972101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
152016000972601/14/16 Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
162016000079501/07/16 Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
172015036109412/17/15 Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
182015034295212/03/15 Treatment of chronic neutrophilic leukemia (cnl) and atypical chronic myeloid leukemia (acml) by inhibitors of jak1
192015034449712/03/15 Processes of preparing a jak1 inhibitor and new forms thereto
202015032953411/19/15 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
212015032956111/19/15 Amido compounds and their use as pharmaceuticals
222015031518511/05/15 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
232015030749310/29/15 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
242015029170110/15/15 Methods for treating disorders associated with human signal peptide-containing molecules
252015028439010/08/15 N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
262015025079009/10/15 Topical formulation for a jak inhibitor
272015024604609/03/15 Jak1 inhibitors for the treatment of myelodysplastic syndromes
282015023849208/27/15 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
292015022537508/13/15 Cyclopropylamines as lsd1 inhibitors
302015022537908/13/15 Cyclopropylamines as lsd1 inhibitors
312015022539408/13/15 Cyclopropylamines as lsd1 inhibitors
322015022540108/13/15 Cyclopropylamines as lsd1 inhibitors
332015022541108/13/15 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
342015021817408/06/15 Processes for preparing jak inhibitors and related intermediate compounds
352015021069207/30/15 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
362015019037807/09/15 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
372015018380507/02/15 Processes and intermediates for making a jak inhibitor
382015017560406/25/15 Tricyclic heterocycles as bet protein inhibitors
392015016490006/18/15 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
402015014834205/28/15 Bicyclic heterocycles as bet protein inhibitors
412015014834805/28/15 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
422015014837205/28/15 Bicyclic heterocycles as bet protein inhibitors
432015014837505/28/15 Bicyclic heterocycles as bet protein inhibitors
442015013367405/14/15 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
452015008763203/26/15 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as jak inhibitors
462015008766203/26/15 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
472015006544703/05/15 Survival benefit in patients with solid tumors with elevated c-reactive protein levels
482015006548403/05/15 Sustained release dosage forms for a jak1 inhibitor
492015005726502/26/15 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
502015002505601/22/15 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
512015001717301/15/15 Antibodies to human transmembrane proteins
522015001154001/08/15 Tricyclic heterocycles as bet protein inhibitors
532015000416501/01/15 Secreted proteins
542014037729212/25/14 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
552014037840012/25/14 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
562014037121612/18/14 Purinone derivatives as hm74a agonists
572014034303011/20/14 Bipyrazole derivatives as jak inhibitors
582014031596210/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
592014027503009/18/14 Tricyclic heterocycles as bet protein inhibitors
602014027503109/18/14 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
612014027512709/18/14 Substituted heteroaryl fused derivatives as pi3k inhibitors
622014025694109/11/14 Processes and intermediates for making a jak inhibitor
632014024913209/04/14 Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
642014024208608/28/14 Polynucleotides encoding signal peptide-containing molecules
652014024330808/28/14 Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
662014024336008/28/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
672014022727508/14/14 Methods of treating and diagnosing pancreatitis
682014022727808/14/14 Antibodies to human signal peptide-containing proteins
692014022834608/14/14 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
702014022137908/07/14 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
712014020021607/17/14 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
722014020022707/17/14 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
732014018753007/03/14 Aza spiro alkane derivatives as inhibitors of metalloproteases
742014017140506/19/14 Fused pyrazoles as fgfr inhibitors
752014017140906/19/14 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
762014015528806/05/14 Methods for diagnosing cancer
772014015537706/05/14 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
782014015540406/05/14 Piperazinylpiperidine derivatives as chemokine receptor antagonists
792014013535005/15/14 Sustained-release dosage forms of ruxolitinib
802014012119805/01/14 Tricyclic fused thiophene derivatives as jak inhibitors
812014012122205/01/14 Pyrimidinones as pi3k inhibitors
822014006644803/06/14 Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
832014005690602/27/14 Secreted proteins
842014005791202/27/14 Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
852014004581402/13/14 Pyrazine derivatives as fgfr inhibitors
862014003134401/30/14 Azepine inhibitors of janus kinases
872014002366301/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
882014001837401/16/14 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
892014000516601/02/14 Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
902014000521001/02/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
912013034515712/26/13 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
922013034522412/26/13 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
932013032451512/05/13 Imidazotriazines and imidazopyrimidines as kinase inhibitors
942013025319009/26/13 Processes for preparing jak inhibitors and related intermediate compounds
952013025319109/26/13 Processes for preparing jak inhibitors and related intermediate compounds
962013025319309/26/13 Processes for preparing jak inhibitors and related intermediate compounds
972013024378109/19/13 Signal peptide-containing proteins
982013024492709/19/13 Polynucleotides encoding signal peptide-containing molecules
992013024499909/19/13 Substituted heterocyclic compounds
1002013022476908/29/13 Methods of using chemokine panec-1 antibodies
1012013022555608/29/13 Azetidine and cyclobutane derivatives as jak inhibitors
1022013019025007/25/13 Polynucleotides encoding human signal peptide-containing proteins
1032013017759007/11/13 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1042013013768105/30/13 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1052013012324605/16/13 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1062013011623005/09/13 3-aminopyrrolidine derivatives as modulators of chemokine receptors
1072013009614404/18/13 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
1082013005894203/07/13 Human beta-adrenergic receptor kinase polypeptide and methods
1092013005983503/07/13 Heterocyclylamines as pi3k inhibitors
1102013006002603/07/13 Processes and intermediates for making a jak inhibitor
1112013004596302/21/13 Cyclohexyl azetidine derivatives as jak inhibitors
1122013001803401/17/13 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
1132013001806801/17/13 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
1142012032978212/27/12 Azepine inhibitors of janus kinases
1152012030146411/29/12 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
1162012029591211/22/12 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1172012027080910/25/12 Human transmembrane proteins
1182012012285805/17/12 Lactam compounds and their use as pharmaceuticals
1192012004096402/16/12 N-substituted piperidines and their use as pharmaceuticals
1202012003517202/09/12 Purinone derivatives as hm74a agonists
1212012001493701/19/12 Human beta-adrenergic receptor kinase polypeptide and methods
1222012001592801/19/12 Amido compounds and their use as pharmaceuticals
1232011025121510/13/11 Macrocyclic compounds and their use as kinase inhibitors
1242011021296709/01/11 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
1252011020775408/25/11 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
1262011013678106/09/11 Imidazotriazines and imidazopyrimidines as kinase inhibitors
1272011008681004/14/11 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1282011008215904/07/11 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1292011005321703/03/11 Polynucleotides encoding signal peptide-containing molecules
1302010027933311/04/10 Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
1312010025611410/07/10 Amido compounds and their use as pharmaceuticals
1322010024067109/23/10 Substituted heterocyclic compounds
1332010020303908/12/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1342010019080407/29/10 Macrocyclic compounds and their use as kinase inhibitors
1352010017390107/08/10 Substituted heterocyclic compounds
1362010013740106/03/10 2-methylprop anamides and their use as pharmaceuticals
1372010011950305/13/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1382010009961704/22/10 Secreted proteins
1392009031840512/24/09 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
1402009029194611/26/09 Lactam compounds and their use as pharmaceuticals
1412009028677411/19/09 Purinone derivatives as hm74a agonists
1422009028677811/19/09 Macrocyclic compounds and their use as kinase inhibitors
1432009027468011/05/09 Human phospholipases
1442009023390309/17/09 Azetidine and cyclobutane derivatives as jak inhibitors
1452009021576608/27/09 Tetracyclic inhibitors of janus kinases
1462009019788708/06/09 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1472009018195907/16/09 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1482009012464905/14/09 Aza spiro alkane derivatives as inhibitors of metalloproteases
1492009008844604/02/09 Purinone derivatives as hm74a agonists
1502009007626903/19/09 Purinone derivatives as hm74a agonists
1512012026367610/18/12 Compositions, methods and kits relating to her-2 cleavage
1522012005807903/08/12 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1532012001498901/19/12 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1542011031147912/22/11 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1552011022321009/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1562011022415709/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1572011017227907/14/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1582011016518807/07/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1592011008683504/14/11 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1602009029880812/03/09 Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1612009019786908/06/09 Azepine inhibitors of janus kinases



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###